Follow-up of COVID-19 Vaccine Response in Strasbourg University Hospitals

University Hospital, Strasbourg, France800 enrolled

Overview

Vaccination remains the main promising measure to fight against the COVID-19 pandemic. The presumed efficacy of the vaccines is quite remarkable since it varies between 62 and 95%. There is increasing evidence that sex-specific effects may lead to different outcomes of vaccine safety and efficacy. However, sex-disaggregated data after COVID-19 vaccine are lacking. The first purpose of the study is to determine antibody titers against SARS-CoV-2 spike after COVID-19 vaccination. The secondary purpose is to identify predictor factors of immune response including age, gender and biological factors.

Study Type

OBSERVATIONAL

Enrollment

800

Conditions

COVID-19 Vaccines

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: \- Any person, male or female, over 18 years of age who underwent vaccination and * anti-SARS-CoV-2 serological test after vaccination * having already given their consent for their biological resources to be: * stored in a biocollection of the Microbiology Technical Platform (PTM) having received an approval from the CPP Est-IV and declared to the Ministry of Education and Research under reference No. DC2009-1002; * subsequently reused, as well as the anonymized associated data, for research purposes Exclusion Criteria: * Inability to give clear information (person in an emergency, difficulty understanding the subject, etc.) * Person under safeguard of justice * Person under guardianship or curatorship-

Follow-up of COVID-19 Vaccine Response in Strasbourg University Hospitals

Overview

Conditions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Central Contacts